Report Description Table of Contents Moyamoya Disease Market: How Are Earlier Diagnosis and Cerebral Bypass Access Reshaping Specialized Care? According to Strategic Market Research, the Global Moyamoya Disease Market was valued at USD 618.50 million in 2025 and is projected to reach USD 927.01 million by 2032, expanding at a CAGR of 6.0% during 2026–2032. Increasing demand for early diagnosis, cerebral revascularization surgery, neurovascular imaging, and long-term neurological care is supporting market growth. Moyamoya disease affects blood vessels supplying the brain and increases the risk of strokes, creating sustained demand for specialized neurosurgical treatment, stroke prevention, and regular patient monitoring. According to a September 2026 study published in BMJ Public Health, researchers examined Moyamoya disease cases across 210 hospitals in China's Jiangxi Province. The study recorded 18,693 hospitalizations involving 11,140 newly identified patients, highlighting the need for early diagnosis, brain imaging, and specialized neurological treatment. In the United States, Mayo Clinic reported in April 2026 that its specialists evaluate and treat more than 170 Moyamoya disease patients annually. This shows continued demand for brain scans, specialist consultations, surgery, and long-term patient care. Brain bypass surgery is one of the main treatments for Moyamoya disease. An April 2026 multicenter study examined 567 surgically treated brain hemispheres, including 523 adult and 44 pediatric hemispheres. The findings highlight the role of surgery in improving blood supply to the brain and supporting treatment across different age groups. The Global Moyamoya Disease Market through 2032 will be supported by earlier diagnosis, increasing access to brain bypass surgery, stroke prevention, and long-term patient monitoring. These treatment needs create opportunities for specialized hospitals, neurological imaging services, and neurosurgical procedures. How Are Leading Clinical Segments and Emerging Treatment Approaches Reshaping the Moyamoya Disease Market? By Disease Type: Ischemic Cases Lead as Asymptomatic Detection Expands Largest Subsegment – Ischemic Moyamoya Disease Ischemic Moyamoya Disease dominates the disease-type category of the global Moyamoya Disease Market, accounting for 67% of the market, equivalent to approximately USD 414.39 million in 2025, with an anticipated CAGR of 5.8% during 2026–2032. Characterized by progressive narrowing of the internal carotid arteries and their major branches, ischemic Moyamoya disease reduces cerebral blood flow, resulting in transient ischemic attacks (TIAs), ischemic strokes, and chronic cerebral hypoperfusion. Its clinical prevalence supports substantial utilization of diagnostic imaging, cerebral revascularization procedures, and long-term neurological monitoring. Fastest-Growing Subsegment – Asymptomatic Moyamoya Disease Asymptomatic Moyamoya Disease accounted for approximately 9% of the global Moyamoya Disease Market, representing USD 55.67 million in 2025, and is projected to register the fastest CAGR of 7.5% during 2026–2032. Characterized by progressive cerebral arterial narrowing and abnormal collateral vessel formation without noticeable neurological symptoms, asymptomatic Moyamoya disease is gaining clinical importance through early diagnosis, advanced cerebrovascular imaging, and proactive stroke prevention. Increasing use of MRI, magnetic resonance angiography, and cerebral perfusion assessments supports earlier identification, continuous risk monitoring, and individualized preventive management. By Treatment: Cerebral Revascularization Leads Treatment Expenditure Largest and Fastest-Growing Subsegment – Surgical Treatment Surgical treatment dominates the global Moyamoya Disease Market, accounting for 71% of the market, valued at approximately USD 439.14 million in 2025, and is projected to expand at a CAGR of 6.3% during 2026–2032. Surgical revascularization remains the primary and most effective therapeutic approach for Moyamoya disease, focusing on restoring cerebral blood flow, preventing recurrent ischemic strokes, and reducing intracranial hemorrhage risks. Increasing utilization of direct, indirect, and combined bypass procedures, alongside advancements in neurosurgical techniques, continues to strengthen its clinical importance and market leadership. By Surgery: Direct Bypass Leads as Combined Revascularization Expands Largest Subsegment – Direct Revascularization Direct revascularization dominates the surgical treatment category in the Moyamoya Disease Market, accounting for 42% of surgical treatment value, equivalent to approximately USD 184.44 million in 2025, with a projected CAGR of 5.6% during 2026–2032. The procedure primarily involves extracranial-intracranial (EC-IC) bypass surgery, particularly superficial temporal artery-to-middle cerebral artery (STA-MCA) anastomosis, which immediately improves cerebral blood flow to ischemic brain regions. Its ability to rapidly restore cerebral perfusion and reduce recurrent ischemic complications supports its prominent role in surgical management. Fastest-Growing Subsegment – Combined Revascularization Combined revascularization accounted for 27% of the Moyamoya Disease Market’s surgical treatment category, valued at USD 118.57 million in 2025, and is projected to register the fastest CAGR of 7.3% during 2026–2032. The procedure integrates direct bypass, typically superficial temporal artery–middle cerebral artery (STA-MCA) anastomosis, with indirect techniques such as encephaloduroarteriosynangiosis or pial synangiosis. Its ability to provide immediate cerebral blood flow restoration while promoting long-term collateral vessel formation supports increasing clinical adoption for managing progressive cerebrovascular insufficiency in Moyamoya disease. By Diagnosis: MRI/MRA Leads Noninvasive Assessment and Monitoring Largest and Fastest-Growing Subsegment – MRI/MRA MRI/MRA represents the largest and fastest-growing diagnostic category in the global Moyamoya Disease Market, accounting for 49% of the market, valued at approximately USD 303.07 million in 2025, and is projected to expand at a CAGR of 6.8% during 2026–2032. MRI and MRA serve as essential noninvasive imaging techniques for diagnosing Moyamoya disease, assessing cerebral vascular abnormalities, determining disease progression, and monitoring treatment outcomes. Their ability to visualize arterial narrowing and collateral vessel formation supports early detection, clinical decision-making, and long-term patient management. By End User: Hospitals Lead as Specialized Neurovascular Clinics Expand Largest Subsegment – Hospitals Hospitals dominate the end-user category in the global Moyamoya Disease Market, accounting for a 76% market share, equivalent to approximately USD 470.06 million in 2025, with an anticipated CAGR of 5.8% during 2026–2032. Their leadership is supported by comprehensive diagnostic capabilities, advanced neurovascular imaging, specialized surgical revascularization procedures, and multidisciplinary patient management. Increasing utilization of direct and indirect cerebral bypass surgeries, alongside postoperative neurological monitoring, rehabilitation services, and long-term follow-up care, further strengthens hospitals’ position as the primary treatment centers for Moyamoya disease. Fastest-Growing Subsegment – Specialty Clinics Specialty clinics accounted for a 16% market share, equivalent to approximately USD 98.96 million in 2025, and are projected to register the fastest CAGR of 7.3% during 2026–2032. Their growing prominence reflects the specialized nature of Moyamoya disease, which requires advanced cerebrovascular evaluation, high-volume surgical expertise, and multidisciplinary care. Specialized neurovascular clinics facilitate early diagnosis, individualized revascularization planning, and long-term neurological monitoring, strengthening their role in improving treatment accessibility, clinical outcomes, and continuity of care for patients with complex cerebrovascular conditions. By Geography: Asia-Pacific Leads Disease Recognition and Surgical Care Largest and Fastest-Growing Region – Asia-Pacific Asia-Pacific dominates the global Moyamoya Disease Market, accounting for approximately 46% of the global market, valued at USD 284.51 million in 2025, and is projected to grow at a CAGR of 6.5% during 2026–2032. The region’s leadership reflects higher disease prevalence in East Asian populations, particularly Japan, China, and South Korea, alongside increasing clinical recognition, improved diagnostic imaging, and wider access to cerebral revascularization procedures. Regional variations in diagnosis, treatment accessibility, and specialist neurosurgical infrastructure continue to shape Moyamoya Disease management across Asia-Pacific. How Are Leading MedTech Companies Advancing Neurovascular Imaging, Precision Microsurgery, and Cerebral Revascularization in the Moyamoya Disease Market? Medtronic plc — Neurovascular Technologies and Image-Guided Surgical Solutions Medtronic is a major medical technology supplier with a broad portfolio covering neurovascular intervention, surgical navigation, and neurological treatment technologies. Its Pipeline Embolization Device, Solitaire revascularization devices, and neurovascular access systems support the management of selected cerebrovascular disorders, particularly aneurysms and acute ischemic stroke. These technologies demonstrate the company's expertise in neurovascular treatment, although cerebral bypass surgery for Moyamoya disease involves a distinct clinical approach. Medtronic's StealthStation surgical navigation platform supports image-guided neurosurgical procedures, while its broader neurological technology capabilities contribute to advanced operating-room infrastructure. The company's commercial opportunities relevant to Moyamoya disease primarily arise from neurosurgical technology adoption, specialized procedural equipment, and hospital investment in complex neurological care. Its global distribution network and established relationships with tertiary hospitals support access to specialized neurovascular treatment centers. Stryker Corporation — Neurovascular Intervention and Advanced Surgical Instrumentation Stryker maintains a significant presence in neurovascular devices and specialized surgical technologies. Its Trevo NXT ProVue Retriever, Neuroform Atlas Stent System, and Target detachable coils are designed for selected neurovascular interventions, including ischemic stroke thrombectomy and aneurysm treatment. These products serve related cerebrovascular applications rather than routine Moyamoya revascularization surgery. Stryker's broader neurosurgical portfolio includes SONOPET ultrasonic aspirators, surgical instruments, and operative visualization technologies used across complex cranial procedures. Advanced instrumentation and microsurgical operating capabilities are commercially relevant to hospitals performing cerebral bypass surgery. Stryker's position in neurovascular intervention and neurosurgical equipment enables participation in hospital procurement programs serving specialized cerebrovascular care. Other Companies Supporting Moyamoya Disease Diagnosis and Treatment: Johnson & Johnson MedTech (Cerenovus): Supplies neurovascular technologies, including the EMBOTRAP revascularization device and vascular access systems, supporting specialized cerebrovascular intervention capabilities. Terumo Corporation: Provides angiographic catheters, guidewires, and vascular access technologies used in diagnostic cerebral angiography and selected neurovascular procedures. B. Braun Melsungen AG (Aesculap): Manufactures precision microsurgical instruments, vascular clips, and neurosurgical equipment relevant to delicate cerebral vessel dissection and bypass procedures. Integra LifeSciences Holdings Corporation: Supplies specialized neurosurgical instruments, cranial access technologies, and surgical equipment supporting complex intracranial procedures. How Are Emerging Therapeutic Approaches and Precision Neurosurgical Innovations Transforming Moyamoya Disease Treatment? Advanced Direct Revascularization Surgery (EC–IC Bypass) Direct revascularization involves connecting an extracranial artery, typically the superficial temporal artery, to an intracranial artery to immediately improve cerebral blood supply. Advancements in microsurgical instruments, high-magnification visualization, and vascular suturing techniques are enhancing procedural precision. This approach is particularly relevant for selected adult patients with reduced cerebral perfusion and recurrent ischemic symptoms, supporting opportunities for specialized microsurgical equipment manufacturers. Indirect Revascularization and Collateral Vessel Formation Indirect revascularization techniques, including encephaloduroarteriosynangiosis (EDAS) and pial synangiosis, encourage the gradual development of new blood vessels by placing vascularized tissues near the brain surface. These procedures are particularly established in pediatric Moyamoya treatment, where collateral circulation can develop over several months. Improvements in surgical planning and postoperative perfusion assessment support more individualized evaluation of treatment effectiveness. Combined Revascularization Techniques Combined revascularization integrates direct arterial bypass with indirect vascular tissue placement, providing immediate blood-flow improvement alongside longer-term collateral vessel formation. This approach is receiving increasing clinical attention for selected patients requiring comprehensive cerebral perfusion restoration. Its procedural complexity supports the utilization of advanced operating microscopes, microvascular instruments, and intraoperative imaging systems. Minimally Invasive Technologies and Image-Guided Microsurgery Innovations in surgical visualization, indocyanine green fluorescence angiography, microvascular Doppler ultrasound, and intraoperative blood-flow monitoring enable surgeons to assess vessel patency and cerebral circulation during bypass procedures. These technologies improve real-time surgical decision-making and support precise microvascular anastomosis. Their application represents technological refinement of established revascularization surgery rather than replacement with fully minimally invasive treatment. Personalized Antiplatelet and Medical Management Antiplatelet medicines, particularly aspirin, are used in selected patients to manage ischemic risk, depending on clinical presentation and hemorrhagic considerations. Individualized medical management also includes blood-pressure control, headache treatment, and neurological monitoring. Research into optimized antiplatelet strategies and patient selection may improve supportive management, although medication does not reverse the underlying progressive arterial narrowing. Stem Cell Therapy and Regenerative Medicine Stem cell-based therapies represent an investigational treatment direction focused on encouraging angiogenesis, supporting vascular repair, and reducing neurological injury. Research is exploring the potential role of mesenchymal stem cells and their secreted biological factors in promoting cerebral microvascular development. Clinical effectiveness, long-term safety, and appropriate treatment protocols remain under investigation, positioning regenerative medicine as a longer-term opportunity rather than an established therapeutic option. Advanced Cerebral Perfusion Imaging and Personalized Treatment Planning Emerging applications of arterial spin labeling MRI, perfusion MRI, SPECT, and quantitative cerebral blood-flow assessment are improving the evaluation of cerebrovascular impairment. These technologies help clinicians identify patients who may benefit from revascularization, select appropriate surgical strategies, and monitor postoperative perfusion changes. Their increasing integration into specialized neurological care supports more precise clinical decisions and continued investment in advanced neuroimaging infrastructure. Analyst Commentary: How Will Perfusion Imaging and Timely Bypass Expand Specialized Care? The Moyamoya Disease Market is increasingly shifting toward precision cerebrovascular care, where early identification of cerebral perfusion abnormalities and timely surgical intervention are becoming critical treatment priorities. The strongest commercial opportunities lie in advanced microvascular bypass technologies, intraoperative blood-flow visualization, specialized pediatric neurosurgery, and long-term neurovascular monitoring. Expanding access to multidisciplinary stroke centers and personalized revascularization strategies will be instrumental in improving clinical outcomes and strengthening the adoption of specialized neurological treatment services. Moyamoya Disease Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 618.50 Million Revenue Forecast in 2032 USD 927.01 Million Overall Growth Rate CAGR of 6.0% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Disease Type, By Treatment, By Surgery, By Diagnosis, By End User, By Geography By Disease Type Ischemic Moyamoya Disease, Hemorrhagic Moyamoya Disease, Asymptomatic Moyamoya Disease By Treatment Surgical Treatment, Medical Treatment, Supportive Treatment By Surgery Direct Revascularization, Indirect Revascularization, Combined Revascularization By Diagnosis MRI/MRA, Digital Subtraction Angiography (DSA), CT Angiography (CTA) By End User Hospitals, Specialty Clinics, Diagnostic Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Earlier diagnosis through neurovascular imaging, expanding access to cerebral revascularization surgery, adoption of combined bypass techniques, investment in specialized stroke and neurosurgical centers, long-term neurological monitoring and rehabilitation requirements Customization Option Available upon request Frequently Asked Question About This Report Q1. Which treatment category accounts for the largest market share? A1. Surgical treatment leads with an estimated 71% share in 2025. Cerebral revascularization procedures concentrate spending in specialist hospitals with bypass expertise. These services create purchasing requirements for microsurgical instruments, operative visualization and perioperative monitoring equipment. Q2. How are imaging advancements influencing industry development? A2. Improved vascular and perfusion imaging helps specialists assess patients, plan surgery and monitor recovery. MRI/MRA is projected to grow at 6.8% annually during 2026–2032 within the diagnostic category. Repeated assessments create opportunities for imaging providers alongside initial diagnostic examinations. Q3. What innovations are creating new opportunities in the market? A3. Combined revascularization and intraoperative blood-flow assessment are important areas of development. Better visualization helps surgical teams assess vessel connections during bypass procedures. Suppliers can compete through precision instruments and monitoring technologies suited to specialized operating rooms. Q4. Why do hospitals remain the main customers in the market? A4. Hospitals hold an estimated 76% share in 2025 because complex care requires coordinated imaging, neurosurgery and postoperative monitoring. Their concentration of specialist teams and equipment supports treatment delivery. Outpatient specialty clinics complement this role through assessment and long-term surveillance. Q5. Which regional factors are supporting market growth? A5. Asia-Pacific leads with an estimated 46% share in 2025. Greater disease recognition in Japan, China and South Korea supports diagnostic and surgical activity. Expanding neurosurgical capabilities in India also create opportunities, although access to specialist care varies across the region. Q6. What factors should businesses consider before entering this industry? A6. Commercial opportunities are closely tied to specialist referral networks and hospital investment in cerebral bypass capabilities. Businesses should distinguish equipment used directly in diagnosis and surgery from devices serving adjacent stroke or aneurysm procedures. Product relevance and access to experienced treatment centers will shape adoption. Sources: Japan Ministry of Health, Labour and Welfare – Recorded 13,916 Moyamoya Disease Medical Subsidy Certificate Holders at the End of Fiscal Year 2024, Representing Patients Within the Designated-Disease Assistance Program MHLW / e-Stat – Medical Subsidy Certificate Holders by Disease and Age Group, FY2024 Kyoto University Hospital – Reported 195 Moyamoya Disease Admissions and 60 Moyamoya Operations During 2025, Providing Hospital-Level Evidence of Specialized Treatment Demand Kyoto University Hospital – Moyamoya Disease Support Center: Patient Admissions and Surgical Activity Japan Ministry of Health, Labour and Welfare – Reports Familial Occurrence in Approximately 10–20% of Moyamoya Cases and a Male-to-Female Ratio of 1:2.5, Supporting the Relevance of Family Assessment and Targeted Diagnosis MHLW – Moyamoya Disease: Epidemiology, Diagnostic Criteria, and Treatment Approaches Sree Chitra Tirunal Institute for Medical Sciences and Technology, Government of India – Identifies MRI, Digital Subtraction Angiography, CT Angiography, and Selected Perfusion Studies as Investigations Used in Moyamoya Assessment SCTIMST – Moyamoya Disease: Diagnostic Imaging and Information for Medical Professionals Japan National Cerebral and Cardiovascular Center – Uses SPECT and PET Cerebral Circulation Assessment to Evaluate Moyamoya Patients for Bypass Surgery and Provides Long-Term Postoperative Follow-Up NCVC – Moyamoya Disease: Cerebral Perfusion Assessment, Bypass Surgery, and Continuing Care Transonic – Summarizes a Historical Stanford Study Involving 496 Revascularization Procedures in 292 Moyamoya Patients, With Its Charbel Micro-Flowprobe Used for Intraoperative Blood-Flow Measurement Transonic – Blood-Flow Monitoring During Direct Revascularization for Moyamoya Disease Leica Microsystems – Documents GLOW800 Augmented Reality Fluorescence Use During Bypass Surgery in a 35-Year-Old Moyamoya Patient, Supporting Vessel Selection and Intraoperative Assessment of Bypass Patency Leica Microsystems – GLOW800 Fluorescence in the Surgical Treatment of Moyamoya Disease Canon Medical Systems – Reports Clinician Experience Using Its Hi-Def Angiography Detector to Visualize Abnormal Vessels Measuring Approximately 100–200 µm in Moyamoya Patients Canon Medical – Hi-Def Detector Applications in Moyamoya Vascular Imaging ZEISS – July 2026 Evidence Compendium Includes an April 2026 Retrospective Study of 26 Moyamoya Patients Evaluating FLOW800 Imaging and Pressure-Wire Assessment as Predictors of Postoperative Cerebral Perfusion Abnormalities ZEISS – Updated Evidence on ICG Fluorescence Imaging in Moyamoya Disease and Cerebral Bypass Surgery Medical Microinstruments – Announced on October 6, 2025 That Three Adults With Moyamoya Disease Underwent Investigational Symani-Assisted Indirect Bypass Surgery in an Early Feasibility Study MMI – First Clinical Cases of Robotic Microsurgical Intracranial Surgery for Moyamoya Disease U.S. National Library of Medicine, ClinicalTrials.gov – Lists Planned Enrollment of 15 Adults in the Symani RESTORE Early Feasibility Study, Evaluating Robotic-Assisted Neurosurgery for Moyamoya Disease Under Study Number NCT07140731 ClinicalTrials.gov – Symani RESTORE Study: Investigational Robotic Surgery for Moyamoya Disease Japan MHLW-Funded CHAMP Registry – Reported 12 Registered Cases in FY2024 Investigating Adult Intracranial Hemorrhage After Childhood Moyamoya Revascularization, Supporting Research Into Long-Term Postoperative Surveillance MHLW Research Database – CHAMP Registry: Long-Term Outcomes After Pediatric Moyamoya Surgery Japan MHLW-Funded Moyamoya P-ChoC Registry – Reported Enrollment of 80 Brain Hemispheres in Its FY2024 Research Report and Extended Registration Through 2028 to Study Hemorrhage Risk and Preventive Bypass Strategies MHLW Research Database – Moyamoya P-ChoC Registry: Cerebrovascular Imaging and Bypass Research. Table of Contents - Global Moyamoya Disease Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Disease Type, Treatment, Surgery, Diagnosis, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Disease Type, Treatment, Surgery, Diagnosis, End User, and Region Earlier Diagnosis, Cerebral Revascularization, and Long-Term Neurological Care Trends Market Share Analysis Leading Players by Market Presence and Competitive Positioning Market Share Analysis by Disease Type, Treatment, Surgery, Diagnosis, and End User Regional Market Share Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Investment Opportunities in the Moyamoya Disease Market Key Developments and Innovations in Neurovascular Care Strategic Partnerships and Neurosurgical Technology Development High-Growth Segments for Investment Opportunities in Cerebral Revascularization and Microsurgical Bypass Procedures Advanced MRI/MRA, Digital Subtraction Angiography, and CT Angiography Intraoperative Blood-Flow Monitoring and Image-Guided Neurosurgery Specialized Pediatric Neurosurgery and Long-Term Neurological Monitoring Emerging Research in Regenerative Medicine and Cerebral Angiogenesis Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Clinical Characteristics of Moyamoya Disease Role of Cerebral Arterial Narrowing and Abnormal Collateral Vessel Formation Stroke Prevention, Cerebral Perfusion Management, and Specialized Neurological Care Research Evidence and Clinical Developments Reported in April 2026 and September 2026 Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Market Assessment (2025) Forecast Modeling and Market Projections (2026–2032) Market Dynamics Key Market Drivers Earlier Diagnosis and Improved Cerebrovascular Imaging Demand for Cerebral Revascularization Surgery Stroke Prevention and Long-Term Neurological Care Expansion of Specialized Neurovascular Centers Increasing Recognition of Moyamoya Disease in Asia-Pacific Challenges and Restraints Impacting Growth Limited Access to Specialized Neurosurgical Services Complexity of Cerebral Bypass Procedures Differences in Diagnostic Infrastructure and Specialist Availability Long-Term Monitoring and Postoperative Care Requirements Emerging Opportunities for Stakeholders Advanced MRI/MRA and Cerebral Perfusion Assessment Direct, Indirect, and Combined Revascularization Techniques Intraoperative Blood-Flow Visualization and Monitoring Specialized Pediatric Cerebrovascular Treatment Regenerative Medicine and Investigational Angiogenesis Approaches Impact of Clinical Practice and Healthcare Infrastructure Role of Antiplatelet Therapy, Blood-Pressure Management, and Neurological Monitoring Impact of Surgical Expertise, Imaging Availability, and Referral Networks Global Moyamoya Disease Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type: Ischemic Moyamoya Disease Hemorrhagic Moyamoya Disease Asymptomatic Moyamoya Disease Market Analysis by Treatment: Surgical Treatment Medical Treatment Supportive Treatment Market Analysis by Surgery: Direct Revascularization Indirect Revascularization Combined Revascularization Market Analysis by Diagnosis: MRI/MRA Digital Subtraction Angiography (DSA) CT Angiography (CTA) Market Analysis by End User: Hospitals Specialty Clinics Diagnostic Centers Market Analysis by Region: Asia-Pacific North America Europe Latin America Middle East & Africa Leading and Fastest-Growing Subsegments Clinical Adoption of Cerebral Revascularization Techniques Diagnostic Imaging and Long-Term Patient Monitoring Trends Regional Market Analysis North America Moyamoya Disease Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment, Surgery, Diagnosis, and End User Specialized Cerebrovascular Centers and Advanced Neuroimaging Multidisciplinary Neurological Care and Surgical Referral Networks Country-Level Breakdown: United States Canada Europe Moyamoya Disease Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment, Surgery, Diagnosis, and End User Specialist Neurosurgical Services and Cerebrovascular Imaging Capabilities Regional Access to Revascularization and Long-Term Neurological Care Country-Level Breakdown: Germany United Kingdom France Italy Rest of Europe Asia-Pacific Moyamoya Disease Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment, Surgery, Diagnosis, and End User Disease Recognition and Specialized Neurosurgical Capabilities Early Diagnosis, Cerebral Bypass Access, and Pediatric Treatment Clinical Evidence from China and Specialized Care in Japan Country-Level Breakdown: China Japan South Korea India Rest of Asia-Pacific Latin America Moyamoya Disease Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment, Surgery, Diagnosis, and End User Access to Tertiary Neurological Facilities and Diagnostic Imaging Specialized Cerebrovascular Treatment and Referral Pathways Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Moyamoya Disease Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment, Surgery, Diagnosis, and End User Investment in Specialized Hospital Infrastructure Availability of Advanced Neurovascular Imaging and Neurosurgical Services Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Medtronic plc Stryker Corporation Johnson & Johnson MedTech (Cerenovus) Terumo Corporation B. Braun Melsungen AG (Aesculap) Integra LifeSciences Holdings Corporation Siemens Healthineers AG GE HealthCare Technologies Inc. Koninklijke Philips N.V. Canon Medical Systems Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Neurovascular Technologies, Surgical Instrumentation, Imaging Capabilities, and Regional Presence Neurosurgical Equipment and Hospital Procurement Analysis Direct, Indirect, and Combined Revascularization Technology Positioning MRI/MRA, DSA, and CTA Diagnostic Technology Positioning Intraoperative Blood-Flow Visualization and Surgical Navigation Technologies Competitive Positioning in Specialized Cerebrovascular Care Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Evidence and Research Developments Reported in April 2026 Clinical Evidence and Research Developments Reported in September 2026 Market Definitions and Segmentation Criteria Regional and Country-Level Coverage List of Tables Market Size by Disease Type, Treatment, Surgery, Diagnosis, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Analysis (2025), and Forecasts (2026–2032) Market Breakdown by Ischemic, Hemorrhagic, and Asymptomatic Moyamoya Disease Market Breakdown by Surgical, Medical, and Supportive Treatment Market Breakdown by Direct, Indirect, and Combined Revascularization Market Breakdown by MRI/MRA, Digital Subtraction Angiography, and CT Angiography Market Breakdown by Hospitals, Specialty Clinics, and Diagnostic Centers Regional Market Breakdown Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Country-Level Market Analysis Across All Covered Regions Competitive Benchmarking of Neurovascular Technology and Imaging Companies Cerebral Revascularization Techniques and Clinical Application Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape and Technology Positioning Growth Strategies Adopted by Key Players Market Share by Disease Type, Treatment, Surgery, Diagnosis, and End User (2025 vs. 2032) Global Moyamoya Disease Care Ecosystem and Value Chain Analysis Direct, Indirect, and Combined Cerebral Revascularization Pathways Diagnostic Workflow Using MRI/MRA, DSA, and CTA Regional Distribution of Specialized Cerebrovascular Care Emerging Neurosurgical Technologies and Cerebral Perfusion Monitoring